Sponsors (3)
The bill strengthens federal PFAS oversight, transparency, phase-outs, enforcement, and research capacity to reduce exposures and speed remediation, but does so at the cost of substantial compliance fees and reporting burdens, increased liability and legal risk for industry, and potential funding/implementation trade-offs that could disproportionately affect small businesses and some regions.
State and local governments, EPA, and communities gain clearer statutory definitions and stronger enforcement tools (definitions of PFAS/manufacturer/user, suspension/revocation authority, citizen suits, fee-funded processing) that should make rulemaking and enforcement more consistent and faster.
Children, pregnant women, low-income people, hospitals, and nearby communities will see reduced PFAS exposures over time because the bill directs National Academies guidance, requires reporting, phases out nonessential PFAS (10-year timeline) and bans many consumer PFAS products within 1–5 years, and allows legal and regulatory actions to remove imminent-risk uses.
Researchers, communities, and municipalities benefit from Centers of Excellence and research hubs (EPA-certified testing, remediation expertise, and R&D coordination) that accelerate development, validation, and deployment of PFAS detection and removal technologies and safer alternatives.
Small manufacturers, importers, and consumers will face substantial compliance costs (reporting, reformulation, phase-outs, testing, and possible price increases), which could drive some small firms out of the market and raise prices for households.
Regulated entities (especially smaller firms) face large statutory fees and potential high daily civil penalties (including a $100,000 default fee framework) and program costs are shifted onto industries rather than general appropriations, raising competitive and affordability concerns.
Manufacturers, managers, and possibly federal employees face increased legal and criminal exposure — criminal penalties (up to 5 years), CERCLA timing and liability extensions, and bankruptcy non-stay rules raise litigation risk and potential severe individual and corporate liability.
Based on analysis of 4 sections of legislative text.
Requires EPA to have the National Academies define essential PFAS uses, authorizes enforcement and penalties, and creates Centers of Excellence for PFAS research and remediation.
Introduced March 19, 2026 by Betty McCollum · Last progress March 19, 2026
Requires the EPA to contract with the National Academies to review scientific evidence and identify which uses of PFAS (per- and polyfluoroalkyl substances) are "essential" and which are not, and to recommend priorities for phaseout and research into safer alternatives. Gives EPA new civil and criminal enforcement tools to stop and penalize unauthorized or harmful PFAS uses, and establishes two Centers of Excellence (a bi‑institutional center with a National Laboratory and a Rural Center) to advance PFAS detection, remediation, and related R&D. Sets definitions for key terms (including a broad definition of "manufacturer" that covers importers and exporters but excludes routine receivers like public water systems), requires the National Academies’ initial review to finish within three years, and directs EPA to consider environmental justice and economic impacts when assessing penalties. The law creates procedures for applications for the Centers, adopts laboratory methods for PFAS detection, and preserves EPA enforcement discretion while enabling citizen suits.